Estimating Prevalence and Detection Cost: Prerequisites for Disease State Management of Attention Deficit Hyperactivity DisorderByEdward T. Heck, PhDOctober 1st 1996
Use of a New Antiepileptic Drug in an HMO: Economic Outcomes from the Payer PerspectiveByEric G. Klein, PharmD,Joseph A. Paladino, PharmDOctober 1st 1996
The Influence of New Devices on the Costs of Interventional ProceduresByWilliam S. Weintraub, MD,Ron Waksman, MD,Jim Benard, RN, MS,Edmund R. Becker, PhD,Patrick D. Mauldin, PhD,Ziyad M. B. Ghazzal, MD,JohnOctober 1st 1996
Patterns of Antidepressant Use and Their Relation to Costs of CareByDavid Thompson, PhD,Don Buesching, PhD,Karl J. Gregor, PharmD, MS,Gerry Oster, PhDOctober 1st 1996
Comparison of a Decision Analytic Model with Results from a Naturalistic Economic Clinical Trial: An Application to Evaluating Alternative AntidepressantsByTimothy R. Hylan, PhD,James G. Kotsanos, MD, MS,John S. Andersen, PhD,Susan H. Brown, PhD,Catherine Copley-Merriman, MS, MBA,Lisa Egbuonu-Davis,October 1st 1996
Comparison of a New Hand-Held Interactive Airway Monitoring System and a Conventional Peak Expiratory Flow Meter in the Management of AsthmaByDavid Lefkowitz, III, MD,John T. Klimas, MD,Robert N. Ross, PhDOctober 1st 1996
The Psychopharmacology of Depression in the Managed Care SettingByNorman Sussman, MD,Ricardo Castaneda, MDOctober 1st 1996
Correspondence regarding, "HEDIS 3.0: Advancing the State of the Art in Health Plan Performance Measurement"ByDeanna F. Sonnenberg,Ying-Ying Meng, DrPH,Author reply by Cary Sennett, MD, PhD and Carolyn Cocotas, RT, MPAOctober 1st 1996
